We are live on !
Find out more
JHC
Jones Hill Capital Portfolio holdings
AUM
$589M
Turnover
70.83%
This Fund
S&P 500
This Quarter Est. Return
-13.76%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$589M
AUM Growth
+$119M
(+25%)
Cap. Flow
+$204M
Cap. Flow % of AUM
Cap. Flow %
34.65%
Top 10 Holdings %
Top 10 Hldgs %
68.09%
Holding
48
New
19
Increased
9
Reduced
5
Closed
15
Avg Time Held
0.2
years
Top 10 Avg Time Held
0.1
years
Top 20 Avg Time Held
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$66.7M |
| 2 |
Travere Therapeutics
TVTX
|
+$58.6M |
| 3 |
Supernus
SUPN
|
+$57.6M |
| 4 |
Celcuity
CELC
|
+$34.8M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$34.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$43.3M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$28.6M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$28.2M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$22.2M |
| 5 |
ANI Pharmaceuticals
ANIP
|
+$19.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
Jones Hill Capital's Q3 2026 Portfolio in Review
As of Q3 2026, Jones Hill Capital held 48 positions worth $589M, up 25% from $470M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Jones Hill Capital deployed $204M of net new capital in Q3 2026, opening 19 new positions and adding to 9 existing holdings. Its largest new stake was BioCryst Pharmaceuticals: 7,083,300 shares worth $59M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $16.4M trimmed.
- Jones Hill Capital's largest Q3 2026 buy was BioCryst Pharmaceuticals: 7,083,300 shares worth $59M.
- Jones Hill Capital added most to Pharvaris in Q3 2026, an estimated $10.8M increase.
- Jones Hill Capital's biggest Q3 2026 reduction was BioMarin Pharmaceuticals, cutting an estimated $16.4M.
- Jones Hill Capital fully exited Gilead Sciences in Q3 2026, selling an estimated $43.3M.
- Jones Hill Capital's ten largest holdings make up 68% of its $589M portfolio in Q3 2026.
- Jones Hill Capital opened 19 new positions and closed 15 in Q3 2026.
- Jones Hill Capital's portfolio value rose 25% quarter-over-quarter to $589M.
Based on Jones Hill Capital's 13F filing for Q3 2026, filed 13 Nov 2026.